Tislelizumab Plus Concurrent Chemoradiation in Older With ESCC

This study was conducted in elderly (≥70 years old) patients with locally advanced esophageal squamous cell carcinoma. Aim to find the difference in efficacy and safety between tirilizumab combined with concurrent chemoradiation and standard concurrent chemoradiation. Concurrent chemoradiation is the standard treatment for elderly esophageal cancer. Tirelizumab is the first-line and second-line standard treatment for advanced esophageal squamous carcinoma. However, the effect of tirilizumab combined with concurrent chemoradiation for elder with locally advanced esophageal squamous cell carcinoma is unkown. In the study, the investigators plan to enroll 136 elderly subjects with locally advanced esophageal cancer from five hospitals in China. The enrolled patients will be randomly divided into two groups: tirilizumab combined with concurrent chemoradiation group (Tislelizumab + radiotherapy + tigio) and concurrent chemoradiation group (radiotherapy + tigio). The treatment efficiency and safety will be evaluated.

NCT Number	NCT06061146
Lead Sponsor	Tianjin Medical University Cancer Institute and Hospital Collaborators: Sichuan Cancer Hospital and Research Institute, Shanxi Province Cancer Hospital, Henan Cancer Hospital, Hunan Cancer Hospital, The First Affiliated Hospital with Nanjing Medical University
Conditions	Esophageal Cancer
Enrollment	136 participants
Start Date	2023-10-05
Primary Completion	2024-10-01 (estimated)
Study Completion	2026-10-01 (estimated)
Updated on ClinicalTrials.gov	2023-12-26